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of Sjögren’s Syndrome. PLoS ONE 12(2):
e0170249. doi:10.1371/journal.pone.0170249
Editor: Masataka Kuwana, Nippon Medical School,
JAPAN

1 Department of Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States of America,
2 King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia, 3 Arthritis and Clinical Immunology
Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of
America, 4 US Air Force 59th Medical Wing, Joint Base San Antonio-Lackland Air Force Base, San Antonio,
Texas, United States of America, 5 Department of Oral Diagnosis and Radiology, University of Oklahoma
College of Dentistry, Oklahoma City, Oklahoma, United States of America, 6 Department of Medicine,
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America,
7 Department of Oral Pathology, University of Oklahoma College of Dentistry, Oklahoma City, Oklahoma,
United States of America, 8 Department of Oral Surgery, University of Minnesota School of Dentistry,
Minneapolis, Minnesota, United States of America, 9 Hennepin County Medical Center, Minneapolis,
Minnesota, United States of America, 10 Division of Rheumatology, Cedars-Sinai Medical Center, Los
Angeles, California, United States of America, 11 Department of Oral Medicine, Carolinas Medical Center,
Charlotte, North Carolina, United States of America, 12 Department of Veterans Affairs Medical Center,
Oklahoma City, Oklahoma, United States of America
* Astrid-Rasmussen@omrf.org

Abstract

Received: September 7, 2016
Accepted: December 31, 2016
Published: February 6, 2017
Copyright: © 2017 Stone et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: De-identified data is
available within the limits offered to study
participants by the governing institutional review
and privacy boards. Data are available from the
Oklahoma Medical Research Foundation
Institutional Review Board for researchers who
meet the criteria for access to confidential data.
Contact information: Janice Gales, RN, BSN, MS,
CCRP, CIP. IRB Administrator. IRB@omrf.org.
Funding: This work was supported in part by
National Institutes of Health [grant numbers

Objectives
To assess the association of smoking habits with the clinical, serological, and histopathological manifestations of Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca).

Methods
Cross-sectional case-control study of 1288 patients with sicca symptoms (587 SS and 701
non-SS sicca) evaluated in a multi-disciplinary research clinic. Smoking patterns were
obtained from questionnaire data and disease-related clinical and laboratory data were
compared between current, past, ever, and never smokers.

Results
Current smoking rates were 4.6% for SS patients compared to 14.1% in non-SS sicca
(p = 5.17x10E-09), 18% in a local lupus cohort (p = 1.13x10E-14) and 16.8% in the community (p = 4.12x10E-15). Current smoking was protective against SS classification (OR
0.35, 95%CI 0.22–0.56, FDR q = 1.9E10-05), focal lymphocytic sialadenitis (OR 0.26,
95%CI 0.15–0.44, FDR q = 1.52x10E-06), focus score 1 (OR 0.22, 95%CI 0.13–0.39,
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FDR q = 1.43x10E-07), and anti-Ro/SSA(+) (OR 0.36, 95%CI 0.2–0.64, FDR q = 0.0009);
ever smoking was protective against the same features and against anti-La/SSB(+) (OR
0.52, 95%CI 0.39–0.70, FDR q = 5.82x10E-05). Duration of smoking was inversely correlated with SS even after controlling for socioeconomic status, BMI, alcohol and caffeine
consumption.
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Current tobacco smoking is negatively and independently associated with SS, protecting
against disease-associated humoral and cellular autoimmunity. The overall smoking rate
amongst SS patients is significantly lower than in matched populations and the effects of
smoking are proportional to exposure duration.
In spite of the protective effects of tobacco on SS manifestations, it is associated with
other serious comorbidities such as lung disease, cardiovascular risk and malignancy, and
should thus be strongly discouraged in patients with sicca.

Conclusions

Introduction
Tobacco use creates a tremendous burden on the health care system and is the largest noncommunicable source of disease globally; annual tobacco-attributable deaths surpassed 5 million in 2010.[1, 2] Cigarette smoking has wide-ranging effects on the user depending on both
extrinsic and intrinsic factors, with a well-described influence on oncogenesis, pulmonary
function, vascular health, and immune response. [3–10] The mechanisms of disease may be as
diverse as the contents of cigarette smoke; carbon monoxide, cyanide, nicotine, benzene, formaldehyde, methanol, ammonia, tar and nearly 4000 other chemicals identified in cigarette
smoke.[11]
The dysregulation of immune and inflammatory responses caused by tobacco results in the
association of smoking with various conditions that have inflammatory or autoimmune mechanisms as part of their pathophysiology.[9] Perhaps the best examples of associations of current tobacco smoking with increased incidence or severity of disease are with rheumatoid
arthritis,[7, 8, 12–15] Crohn’s disease,[16] and multiple sclerosis.[17] The underlying mechanisms that have been postulated for this exacerbated inflammatory or autoimmune response
include hypoxia and oxidative stress,[18] induction of pro-inflammatory cytokines and autoantibodies,[9] and epigenetic changes.[19]
However, despite leukocytosis and increases in markers of inflammation such as C-reactive
protein in chronic smokers, there is impairment of some aspects of immune function and
increased susceptibility to certain infections.[10] In some conditions, such as ulcerative colitis,
[16] Behçet’s disease,[20] and sarcoidosis,[21] there is a negative correlation between smoking
and disease activity or diagnosis. It is likely that specific gene-environment interactions for
each disease are determinant in the effect that smoking exerts on the phenotype of inflammatory conditions.[8]
Second in prevalence among the rheumatic autoimmune diseases,[22] Sjögren’s syndrome
(SS) is a chronic, systemic disease with a prototypical clinical presentation of xerostomia and
xerophthalmia, associated with immune mediated dysfunction of the salivary and lacrimal
glands.[23] Hallmarks of the autoimmune nature of SS are characteristic lymphocytic infiltrates of the salivary and lacrimal glands and the presence of circulating autoantibodies, mainly
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anti-Ro/SSA and anti-La/SSB,[24] as well as genetic association to genes involved in innate
and adaptive immunity.[25] In addition to exocrine gland dysfunction, patients with SS have
increased risk of cardiovascular disease,[26] interstitial lung disease and COPD,[27] and a ~20
times higher risk of B cell lymphoma.[23, 28] Few studies have evaluated the role of tobacco
smoking in SS, a relevant consideration given the comorbidities of SS.
A decreased smoking rate in SS has previously been documented but detailed analysis of
tobacco effects on SS manifestations is incomplete. Karabulut, et al.[29] reported a decreased
prevalence of current smoking amongst SS patients in comparison to healthy controls but no
association between smoking and autoantibodies, focus score, or extraglandular involvement.
[29] Nilsson, et al. also found a significantly lower prevalence of smoking amongst SS patients
assessed for COPD when compared to non-SS controls; interestingly, the non-smoking status
of the SS patients was not protective against obstructive and possibly restrictive pulmonary
disease.[27] Two European studies evaluating cardiovascular disease risk in SS reported low
smoking rates,[26, 30] and an inverse correlation of current smoking with presence of anti-Ro/
SSA and anti-La/SSB autoantibodies.[26] Finally, Manthorpe and colleagues[31] did not find
differences in the smoking habits of SS and healthy individuals but determined that smoking at
the time of minor salivary gland (MSG) lip biopsy was associated with lower risk of abnormal
focus score and, to a lesser degree, with absence of circulating anti-Ro/SSA and anti-La/SSB
autoantibodies.
Given the observed effect of tobacco smoking on the clinical manifestations of other autoimmune conditions and its association with conditions that disproportionately affect patients
with SS, we sought to explore the effects of tobacco use on a carefully characterized population
of patients with SS.

Patients and Methods
Study Participants and Ethical Considerations
The study subjects were 1288 voluntary participants in the Sjögren’s Research Clinics (SRC) at
the Oklahoma Medical Research Foundation (n = 1007), the University of Minnesota (n = 214),
Cedars-Sinai Medical Center (n = 57), and the Carolinas Medical Center (n = 10). Each institution’s Institutional Review Board approved all procedures and the participants provided twotiered informed consent prior to entering the study. Initial verbal consent was obtained before
the screening phone interview and the mailing of study paperwork and questionnaires; on the
day of the clinic visit and before any procedure took place, additional written informed consent
was obtained.

Clinical Procedures
The protocols for patient recruitment, assessment, and data collection have been described
previously[32] and include all the tests necessary for SS classification based on the AmericanEuropean Consensus Group 2002 revised criteria[24].
Briefly, candidates for evaluation at the SRC were referred by health care providers or
responded to public advertisement; they included patients already clinically diagnosed with SS
and subjects with subjective dry eyes and dry mouth without a prior diagnosis of the disease.
After explaining the objectives and methods of the study and obtaining verbal consent, trained
personnel assessed the presence of ocular and oral symptoms using a validated telephone questionnaire and determined eligibility. Exclusion criteria followed the AECG classification[24]
and included past head and neck irradiation, hepatitis C infection, acquired immunodeficiency syndrome, pre-existing lymphoma, sarcoidosis, and graft-versus-host disease as well as
pregnancy and inability to provide informed consent. Additional exclusion criteria for this
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study were documented overlapping autoimmune conditions; thus, we only included in the
analysis subjects that met criteria for primary SS or non-SS sicca. Use of anticholinergic medications was not considered as a factor for exclusion, but was documented.
The study subjects participated in multi-specialty clinical evaluation that included oral
examination with measurement of whole unstimulated salivary flow (WUSF), minor salivary
gland lip biopsy, and collection and storage of saliva. The ocular examination included slit
lamp biomicroscopy, Schirmer’s I testing, calculation of the van Bijsterveld (vBS)[33] and ocular staining scores (OSS)[34] by staining of the cornea with fluorescein and the conjunctiva
with lissamine green, and collection and storage of tears. Blood samples were taken for determination of relevant autoantibodies as well as extraction of DNA, RNA, and serum for other
studies[32]. A physician with expertise in rheumatological diseases completed a detailed history and physical examination. If the patient reported a past or current diagnosis of another
autoimmune condition, such as rheumatoid arthritis, mixed connective tissue disease, systemic sclerosis, myositis, primary biliary cirrhosis, multiple sclerosis, or systemic lupus erythematosus (SLE), classification criteria for these illnesses were specifically addressed by history,
review of medical records, and directed diagnostic testing for the corresponding condition.
The histopathologic pattern of the salivary gland biopsy was determined according to the
definitions by Daniels et al[35]:
1. Focal Lymphocytic Sialadenitis: presence of 1 or more dense aggregates of 50 or more lymphocytes (usually several hundred or more), usually located in perivascular or periductal locations. The foci are located adjacent to normal- appearing mucous acini in gland lobes or lobules
lacking duct dilation or interstitial fibrosis and contain no more than a minority proportion of
plasma cells. This diagnosis is assigned when these foci are the only inflammation present in a
specimen, or the most prominent feature. Focus scores are then assigned by assessing the glandular area in each and calculating the number of lymphocytic foci present, per 4 mm2 of glandular area.
2. Non-specific Chronic Inflammation (Sialadenitis): scattered or focal infiltrates of lymphocytes, macrophages, and plasma cells that are not adjacent to normal-appearing acini and
located in gland lobules that exhibit some combination of acinar atrophy, interstitial fibrosis,
duct dilation, and luminal inspissated mucus.
3. Sclerosing Chronic Sialadenitis: An advanced stage of nonspecific chronic sialadenitis
in which interstitial fibrosis, various patterns of chronic inflammation, and acinar atrophy
predominate.
4. Within Normal Limits: diagnosed in minor salivary glands with normal-appearing architecture and scattered plasma cells, but without acinar atrophy and few if any lymphocytes.
5. Granulomatous Inflammation: Clusters of CD-68 positive macrophages, with or without
occasional multinucleated giant cells and without necrosis.
Information about cigarette smoking was collected using a questionnaire mailed to the participants before attendance to the SRC. The questions about smoking addressed current or
past smoking, age of onset, and duration of regular smoking. Questions about the number of
cigarettes smoked on average were only added to the questionnaire in the last 18 months, so
the data are not available for the majority of the study participants (S1 Appendix). Unanswered
or incomplete questions were completed at the time of clinic participation with the help of a
trained clinical coordinator. Smoking behaviors were defined as four categories: subjects
reporting to be smokers at the time of study participation were classified as current smokers,
those that reported a history of smoking but had quit were defined as past smokers while subjects that responded they had not been smokers were named never smokers. Ever smokers
were defined as past plus current smokers. For each case, the time of the first diagnosis of SS or
sicca syndrome (prior clinical diagnosis by referring physician or classification resulting from
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SRC evaluation) was considered in order to establish the temporal relation between smoking
and disease. Multiple potential confounding variables were also assessed and detailed information can be found in the supplemental materials (S1 Appendix).
The comparison groups included a SLE cohort from the same institution with a similar geographic, age, and gender distribution,[36, 37] and community smoking prevalence data from
the Centers for Disease Control (CDC),[38] also selected to match the age and gender distribution of the study cohort.

Statistical Analysis
Count data were analyzed using Fisher’s exact, Pearson’s χ2, or Mann Whitney tests, as appropriate. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using the maximum likelihood estimator (MLE) where applicable. The comparison of smoking prevalence
in SS patients to the community data was done using a proportions (z) test. Comparisons of
AECG criteria between current-past smokers and ever-never smokers were adjusted using the
false discovery rate (FDR) method to correct for multiple testing. Path analysis, logistic regression models, and Random Forest algorithms[39] were used to estimate the marginal effect of
smoking on SS after controlling for potential confounding variables (detailed path analysis
and regression methods in S2 Appendix).

Results
The cohort consisted of 1288 subjects: 596 participants entered the study with a clinical diagnosis of SS that was supported by pSS AECG classification at the SRC in 378 cases (63.4%);
651 had no prior clinical SS diagnosis but 190 (29.1%) met AECG criteria for pSS, while 41 (of
which 19 [46%] were classified as pSS) were uncertain about the diagnostic impression of their
referring physician. Thus, based on our comprehensive research evaluation at the SRC, 587 participants were classified as primary SS and 701 as non-SS sicca. The sociodemographic features
of the participants are shown in Table 1. While SS and non-SS sicca participants had similar gender and ethnicity distributions, the latter were younger and less likely to be Asian (p = 9.39x10E06 and p = 0.007, respectively), and more likely to be Native American (p = 0.03) than subjects
classified as SS.
We observed a significant negative association between both current and previous smoking
status and SS classification. The current smoking rate among SS patients was only 4.6%, while
14.1% of non-SS sicca subjects were current smokers (p = 5.17x10E-09); these rates are in contrast to a SLE cohort from the same institution adjusted for age and gender,[36] in which the current smoking rate was 18% (vs. pSS p = 1.14x10E-14 and vs. non-SS p = 0.031), or to the national
rate for women ages 45–64 of 16.8% (vs. pSS p = 4.12x10E-15 and vs. non-SS p = 0.168). [38]
Approximately 35% percent of SS patients reported ever smoking, a significantly lower proportion than reported amongst the non-SS sicca controls (47%, p = 9.2x10E-06). The proportion of
subjects who were past smokers but quit was not significantly different between SS patients and
non-SS sicca participants (30% vs. 32%; p = 0.43), however, never smokers were more prevalent
amongst SS (65% vs. 53%, p = 0.0003) (Table 1). When comparing current to past smokers, the
current smokers had a significantly lower risk of being classified as SS than past smokers (OR
0.35, 95%CI 0.22–0.56, p = 3.0X10E-06, FDR q = 1.9X10E-05), and ever smokers had a lower
risk than never smokers (OR 0.61, 95%CI 0.49–0.77, p = 9.2x10E-06, FDR q = 5.83E10-05).
To determine if there were confounding factors related to the presence of chronic dryness,
we compared the overall smoking rate of our cohort (irrespective of SS classification) to community data obtained from the CDC National Health Interview Survey;[38] 9.8% of the sicca
cohort smoked in comparison to the reported rate in Oklahoma of 17.2% (p = 2.27XE-12), or
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Table 1. Sociodemographic characteristics and smoking status of study participants with primary Sjögren’s syndrome and non-Sjögren’s sicca.
Primary Sjögren’s Syndrome

Non-Sjögren’s sicca

n = 587

n = 701

56 [47–65]

52 [43–62]

9.39E-06a

547 (93.2%)

643 (91.7%)

0.32b

401 (68.3%)

442 (63.1%)

0.05c

Native American

148 (25.2%)

216 (30.8%)

0.03c

African American

16 (2.7%)

25 (3.6%)

0.43c

Asian

14 (2.4%)

4 (0.01%)

0.007c

559 (95.2%)

680 (97%)

0.13b

27 (4.6%)

99 (14.1%)

5.17E-09b

Past smoker

179 (30.5%)

230 (32.8%)

0.37b

Ever smoked

206 (35.1%)

329 (46.9%)

9.20E-06b

Never smoked

381 (64.9%)

372 (53.1%)

0.0003b

Smoking duration (median years [IQR])

15 [6.75–27]

19 [10–30]

0.0013a

Cessation (median years [IQR])

18 [7.5–30]

16 [5–28]

0.3789a

12 years or less

156 (26.6%)

192 (27.5%)

0.97a

College or equivalent

298 (50.8%)

353 (50.6%)

1.0a

Graduate/Professional or more

121 (20.6%)

150 (21.5%)

0.97a

50,486 [41,422–65,871]

49,560 [40,471–62,707]

0.08a

27.95 [23.47-33-38]

27.62 [16.06–33.28]

0.98a

Age (median years [IQR])
Gender (female)

P value

d

Race

White
e

Ethnicity (non-Hispanic)
Smoking status
Current smoker

Education

Income (median USD [IQR])
BMI (median [IQR])
a
b
c

Mann-Whitney Test
χ2 Test
Fisher’s exact test

d

Some data-points were not available; the percentages are calculated based on the subjects with data recorded.
e
Native-American: Self-referred as either “Native-American” or “More than one race, one of which was Native-American”
BMI: Body Mass Index
doi:10.1371/journal.pone.0170249.t001

the national rate of 16.8% (p = 2.1X10E-11). These results support the notion that dryness,
regardless of the underlying cause, is a deterrent for smoking.
Given the large proportion of Native American patients attending our clinic and their high
smoking rates (national rate for Native American women is 32.5%),[38] we analyzed them separately and found that the overall current smoking rate of all Native American women in the
cohort was significantly lower (11.8%) than expected (p = 3.1x10E-16). Amongst Native Americans, the risk of being classified as SS for current smokers vs. past smokers, and for ever smokers vs. never smokers was also significantly lower (OR = 0.34, 95%CI 0.13–0.67, p = 0.02 and
OR = 0.51, 95%CI 0.33–0.78, p = 0.002, respectively).
Detailed clinical and laboratory features of all participants based on their smoking status
and their descriptive statistics are shown in Table 2.
The most significant differences were identified when comparing objective measures of
autoimmunity (namely, autoantibody presence and focal lymphocytic sialadenitis) between
smokers and non-smokers (Table 3). Current smokers had a lower risk for presence of antiRo/
SSA (OR 0.36, 95%CI 0.20–0.64, p = 0.0004, FDR q = 0.002), hypergammaglobulinemia (OR
0.17, 95% CI 0.05–0.55, p = 0.0008, FDR q = 0.003) and, most notably, for MSG biopsy with a
focus score 1 (OR 0.22, 95%CI 0.13–0.39, p = 7.54x10E-09, FDR q = 1.43x10E-07). These
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Table 2. Sociodemographic, clinical, and serological features of all study participants (irrespective of Sjögren’s classification) based on smoking
status.
Current Smoker
Age (median years [IQR])
Gender (female)

Past Smoker

Ever Smoked

Never Smoked

n = 126

n = 409

n = 535

n = 753

47 [41–55]

57 [48–66]

54 [45–63]

55 [44–63]
703 (93%)

112 (89%)

375 (92%)

487 (91%)

29.25 [20–36]

15 [6–27]

19 [8–30.5]

N/A

Sjögren’s Syndromea

27 (21%)

179 (44%)

206 (39%)

381 (51%)

Subjective dry eyes

123 (98%)

392 (96%)

515 (96%)

720 (96%)

Subjective dry mouth

123 (98%)

397 (97%)

520 (92%)

733 (97%)

Schirmer’s (+)

40 (33%)b

157 (39%)b

197 (38%)b

284 (38%)b

Schirmer’s mm/5min (median [IQR])

10 [5–23.5]

8 [3–15]

8 [4–16]

8 [3–17]

WUSF (+)

60 (48%)b

226 (56%)b

286 (54%)b

409 (55%)b

1.62 [0.7–3.13]

1.26 [0.41–2.9]

1.32 [0.45–3.0]

1.29 [0.42–2.86]

51 (43%)b

169 (44%)b

220 (43%)b

327 (46%)

3 [1–5]

3 [1–5]

3 [1–5]

3 [1–5]

Anti-Ro/SSA

15 (12%)

112 (27%)

127 (24%)

266 (35%)

Anti-La/SSB

12 (10%)

66 (16%)

78 (15%)

185 (25%)

ANA

86 (68%)

261 (64%)

347 (65%)

509 (68%)

Rheumatoid Factor

14 (11%)

83 (21%)

97 (18%)

164 (22%)

Focus score 1

17 (14%)b

158 (42%)b

175 (35%)b

309 (46%)b

Smoking duration (median years [IQR])

WUSF mL/15min (median [IQR])
vBS (+)
vB score (median [IQR])
Auto-antibodies

Histopathology
Focus score (mean±SD)

0.31±1.04

1.40±2.23

1.12±2.04

1.54±2.38

Focal lymphocytic sialadenitis

19 (17%)b

142 (44%)b

161 (37%)b

274 (46%)b

Non-specific chronic inflammation

79 (71%)b

152 (48%)b

231 (54%)b

283 (47%)b

Sclerosing chronic sialadenitis
Normal salivary gland

b

b

3 (3%)

10 (3%)

b

12 (2%)b

b

27 (5%)b

13 (3%)

b

10 (9%)

b

16 (5%)

26 (6%)

Serologic abnormalities
Leukopenia

5 (4%)

24 (6%)

29 (5%)

69 (9%)

Hypergammaglobulinemia (IgG)

3 (2%)

52 (13%)

55 (10%)

103 (14%)

Low C3

2 (2%)

5 (1%)

7 (1%)

21 (3%)

Low C4

5 (4%)

22 (5%)

27 (5%)

ESSDAI score (mean±SD)
ESSPRI score (mean±SD)

2.91±4.18

b

6.69±1.94

b

3.51±5.46

b

6.84±1.65

b

34 (5%)
b

2.97±4.34b

b

6.25±2.21b

3.37±5.18
6.79±1.72

a

Sjögren’s Syndrome: Subjects are classified as primary Sjögren’s Syndrome based on the AECG criteria.[24]

WUSF: Whole Unstimulated Salivary Flow; vBS: van Bijsterveld Score.
b
Some datapoints were not available; the percentages are calculated based on the subjects with data recorded.
doi:10.1371/journal.pone.0170249.t002

protective effects of smoking were consistent when comparing ever vs. never smoking. Ever
smokers were less likely to be anti-Ro/SSA positive (OR 0.57, 95%CI 0.44–0.73, p = 4.47Ex1006, FDR q = 5.82x10E-05), anti-La/SSB positive (OR 0.52, 95%CI 0.39–0.70, p = 6.13x10E-06,
FDR q = 5.82x10E-05), and focus score 1 (OR 0.65, 95%CI 0.52–0.83, p = 0.0005 FDR
q = 0.002). However, no significant differences were encountered in mean ESSDAI or ESSPRI
scores or their individual domains between the different smoking behaviors (data not shown).
More detailed analysis of the effects of smoking on the histopathologic patterns observed in
the MSG biopsy, revealed that current smokers had a lower frequency of focal lymphocytic sialadenitis (OR 0.26, 95%CI 0.15–0.44, p = 1.60x10E-07, FDR q = 1.52x10E-06) but significantly
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Table 3. Risk of classification as Sjögren’s syndrome and presence of associated disease criteria and histopathologic patterns based on smoking
status.
Current Smokers vs. Past Smokers
OR (95%CI)

χ P value

FDR adjusted q value

Sjögren’s Syndromea

0.35 (0.22–0.56)

3.0E10-06

Subjective dry eyes

1.8 (0.51–6.17)

0.36

Subjective dry mouth

1.24 (0.34–4.46)

Schirmer’s (+)

0.76 (0.49–1.15)

Ever Smokers vs. Never Smokers
OR (95%CI)

χ2 P value

FDR adjusted q value

1.9E10-05

0.61 (0.49–0.77)

9.2E10-06

5.83E-05

0.53

1.18 (0.67–2.08)

0.57

0.722

0.74

0.823

0.95 (0.48–1.87)

0.87

0.87

0.18

0.311

0.97 (0.77–1.22)

0.76

0.802
0.624

2

Clinical and Serological features

vBS (+)

0.95 (0.63–1.44)

0.82

0.823

0.92 (0.73–1.15)

0.46

WUSF (+)

0.75 (0.50–1.12)

0.16

0.304

0.96 (0.77–1.21)

0.75

0.802

Anti-Ro/SSA (+)

0.36 (0.20–0.64)

0.0004

0.002

0.57 (0.44–0.73)

4.47E10-06

5.82E-05

Anti-La/SSB (+)

0.55 (0.28–1.05)

0.07

0.166

0.52 (0.39–0.70)

6.13E10-06

5.82E-05

ANA (+)

1.22 (0.79–1.87)

0.36

0.526

0.88 (0.70–1.12)

0.31

0.491

Rheumatoid factor (+)

0.53 (0.30–0.93)

0.02

0.054

0.89 (0.68–1.17)

0.42

0.614

Focus score 1

0.22 (0.13–0.39)

7.54E10-09

1.43E-07

0.65 (0.52–0.83)

0.0005

0.002

Leukopenia (+)

0.66 (0.25–1.78)

0.41

0.556

0.57 (0.36–0.89)

0.013

0.041
0.148

Hypergammaglobulinemia (+)

0.17 (0.05–0.55)

0.0008

0.003

0.72 (0.51–1.02)

0.07

Low C3 (+)

1.30 (0.25–6.80)

0.75

0.823

0.46 (0.20–1.10)

0.07

0.148

Low C4 (+)

0.73 (0.27–1.96)

0.53

0.67

1.12 (0.67–1.89)

0.66

0.784

Histopathologic patterns
Focal lymphocytic sialadenitis

0.26 (0.15–0.44)

1.6E10-07

1.52E10-06

0.70 (0.55–0.91)

0.006

0.023

Non-specific chronic inflammation

2.73 (1.71–4.35)

8.59E10-06

4.08E-05

1.88 (1.0–1.65)

0.05

0.136

Sclerosing chronic sialadenitis

0.86 (0.23–3.19)

0.823

0.823

1.52 (0.68–3.36)

0.301

0.491

Normal salivary gland

1.88 (.83–4.28)

0.126

0.266

1.35 (0.78–2.35)

0.289

0.491

a

Sjögren’s Syndrome: Subjects are classified as primary Sjögren’s Syndrome based on the AECG criteria[24].

WUSF: Whole Unstimulated Salivary Flow; vBS: van Bijsterveld Score. Bolded items are statistically significant.
doi:10.1371/journal.pone.0170249.t003

more non-specific chronic inflammation in the gland than past smokers (OR 2.73, 95%CI
1.71–4.35, p = 8.59x10E-06, FDR q = 4.08x10E-05). These differences were still present but to
a lesser degree when comparing ever to never smokers (Table 3). The proportion of MSG biopsies with sclerosing chronic sialadenitis or normal salivary gland tissue was similar across all
groups and so was the frequency of germinal center-like structures, atrophy, fibrosis, or fatty
infiltration of the glands (data not shown).
Participants with confirmed SS were affected by their smoking status in similar ways to the
effects identified in the complete cohort. Namely, current smokers had significantly lower
rates of minor salivary gland lip biopsies with focus score 1 (p = 0.0009), focal lymphocytic
sialadenitis (p = 0.0084), and of hypergammaglobulinemia (p = 0.048), while they had higher
rates of non-specific chronic inflammation (p = 8.59x10E-06). Similarly, current smokers had
low rates of positive biopsy results when compared to never smokers (p = 0.0095) and higher
frequency of non-specific chronic inflammation (p = 0.027) (Table 4)
In an effort to control for confounding factors, we used logistic regression and two Path
Analysis (PA) models (Fig 1, Table 5 and S2 Appendix) to determine whether the path coefficient from smoking duration to SS was significant after controlling for socioeconomic status
(SES) and body mass index (BMI) as potential confounders. In both instances, smoking duration was independently protective (p = 2.93Ex10-05 and p = 2.33Ex10-05, respectively). In
other words, the longer individuals smoke, the less likely they are to be diagnosed with SS,
regardless of their SES or BMI. Similarly, controlling for caffeine and alcohol intake using a

PLOS ONE | DOI:10.1371/journal.pone.0170249 February 6, 2017

8 / 18

Tobacco Effects on Sjögren’s Syndrome

Table 4. Sociodemographic, clinical, and serological features of study participants with primary Sjögren’s Syndromea based on their smoking
status.

Age (median years [IQR])
Gender (female)
Smoking duration (median years [IQR])

Current

Past

Ever

Never

Smoker

Smoker

Smoked

Smoked

n = 27

n = 179

n = 206

n = 381

54 [44–58]

58 [49–66]

57 [49–66]

56 [46–65]

23 (85%)

162 (91%)

185 (90%)

362 (95%)*

27 [18–35]

14 [6–25]

17 [8–30]

N/A

Subjective dry eyes

27 (100%)

175 (98%)

202 (98%)

376 (99%)

Subjective dry mouth

27 (100%)

177 (99%)

204 (99%)

379 (99%)

Schirmer’s (+)

14 (54%)§

96 (55%)§

110 (55%)§

195 (53%)§

Schirmer’s mm/5min (median [IQR])

5 [3–12]

5 [3–10]

5 [3–10]

5 [2–12]

15 (58%)§

124 (70%)§

139 (68%)§

259 (69%)§

1.33 [0.4–2.95]

0.92 [0.20–2.13]

0.96 [0.25–2.28]

0.88 [0.24–2.21]

12 (50%)§

94 (58%)§

106 (57%)§

231 (65%)

3.5 [2–6.75]

4 [1–7]

4 [1–7]

4 [2–7]

Anti-Ro/SSA

14 (52%)

104 (58%)

118 (57%)

237 (62%)

Anti-La/SSB

10 (37%)

58 (32%)

68 (33%)

163 (43%)

ANA

22 (82%)

141 (79%)

164 (80%)

317 (83%)

Rheumatoid Factor

7 (26%)

65 (36%)§

72 (35%)§

132 (35%)

Focus score 1

15 (60%)§

137 (87%)§***

152 (83%)§**

266 (82%)§**

Focus score (mean±SD)

1.47±2.11

3.06±2.62**

2.85±2.61**

2.87±2.70**

WUSF (+)
WUSF mL/15min (median [IQR])
vBS (+)
vB score (median [IQR])
Auto-antibodies

Histopathology

Focal lymphocytic sialadenitis
Non-specific chronic inflammation
Sclerosing chronic sialadenitis
Normal salivary gland

§

11 (58%)

§

7 (37%)

§

0 (0%)

§

1 (5%)

§

105 (85%) **
§

16 (13%) ****

§

116 (82%) *
§

23 (17%) *

§

2 (2%)

47 (18%)§*

§

6 (2%)§

§

2 (1%)

§

216 (77%)§

1 (1%)

2 (1%)

6 (2%)§

Serologic abnormalities
Leukopenia

4 (15%)

16 (9%)

20 (10%)

49 (13%)

Hypergammaglobulinemia (IgG)

2 (7%)

45 (25%)*

47 (23%)

91 (24%)

Low C3

0 (0%)

3 (2%)

3 (2%)

12 (3%)

Low C4

2 (7%)

14 (8%)

16 (8%)

27 (7%)

ESSDAI score (mean±SD)

2.69±4.31§

3.33±5.20§

3.24±5.07§

3.02±4.11§

ESSPRI score (mean±SD)

6.75±0.96§

6.93±1.75§

6.90±1.66§

6.03±2.25§

a

Sjögren’s Syndrome: Subjects are classified as primary Sjögren’s Syndrome based on the AECG criteria.

WUSF: Whole unstimulated salivary flow; vBS: van Bijsterveld Score.
§
Some datapoints were not available; the percentages are calculated based on the subjects with data recorded.
* p<0.05
**p<0.005
***p<0.0005
****p<0.0001.
doi:10.1371/journal.pone.0170249.t004

logistic regression model showed that smoking duration was independently protective from SS
classification (p = 3.58Ex10-05). A similar analysis of the effect of time since smoking cessation
on SS risk did not demonstrate a significant or independent effect.
Current smoking has a higher impact on SS classification than duration of smoking. The
odds ratio for Sjögren’s syndrome classification in current smokers compared to never smokers is 0.27 (95% CI 0.17–0.42; p = 6.31x10E-10) and 0.35 (95% CI 0.22–0.56; p = 3.0x10E-06)
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Fig 1. Path analysis model used to estimate the effect of smoking duration on SS and the role of potential confounding factors. The standardized
path coefficients, significant odds ratios (OR) and p-values (in bold) are shown next to each path. A. Effect of smoking duration on SS, conditional on
socioeconomic status; B. Model used to estimate the effect of smoking duration on SS, conditional on body mass index.
doi:10.1371/journal.pone.0170249.g001

in comparison to past smokers. The protective effect diminishes after cessation, so past smokers have an OR of 0.80 (95% CI 0.60–0.97; p = 0.026). In the case of smoking duration, the
socioeconomic regression model shows that longer smoking duration results in an OR of Sjögren’s classification of 0.979 (95% CI 0.970–0.989; p = 2.93E-05) and the outcome of the BMI
model shows and OR of 0.977 (95% CI 0.966–0.987; p = 2.33E-05). These effects are significantly different with non-overlapping 95%CI. (Fig 1 and S1 Appendix and S2 Appendix).

Discussion
We explored the smoking behavior of a large cohort of patients with sicca syndrome and identified a strong protective effect of tobacco smoking against disease classification as primary SS
and objective measures of autoimmunity. This effect persisted after correction for multiple
testing and was consistently observed when comparing current to past smoking, and ever to
Table 5. Logistic Regression models exploring the effect of covariates of smoking on the risk of classification as Sjögren’s Syndrome. The only
significant predictor was smoking duration.
Smoking Duration
Estimate

Std Error

z value

P value

Smoking Duration

-0.02

0.01

-4.16

3.14xE10-05

Education

-0.03

0.02

-1.21

ns

Income

0.00

0.00

1.73

ns

Smoking Duration

-0.02

0.01

-4.23

2.33xE10-05

BMI

0.00

0.01

0.11

ns

-0.02

0.004

-4.09

4.3xE10-05

-0.06

0.06

-0.93

ns

-0.08

0.16

-0.47

ns

Model 1:

Model 2:

Model 3:
Smoking

Duration

Alcohol intake
Caffeinated

beverages

BMI: Body Mass Index.
doi:10.1371/journal.pone.0170249.t005
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never smoking. Exposure to tobacco smoke has been associated with a large number of deleterious effects on health. It is a well-known modulator of inflammatory and immune mechanisms and its use has been associated with an increase in disease risk, severity and flares of
rheumatic diseases, in particular rheumatoid arthritis.[7, 8, 12–15] However, the precedent set
by ulcerative colitis, Behçet’s disease, and aphthous stomatitis[16, 20] raises the possibility of a
protective effect of smoking upon the development of some immune-mediated disorders. Few
other studies have focused on the role of tobacco in Sjögren’s syndrome, which is a natural
model to explore given that smoking has also been positively associated with oral and salivary
gland diseases and symptoms of dry eyes.[40, 41]
The mechanism for the observed negative association between the classification of SS and
tobacco use remains to be determined. Our results support the notion that the protective effect
of smoking decreases after cessation since past smokers have intermediate rates of SS classification in comparison to current and never smokers; furthermore, current smoking was a significantly stronger determinant of SS risk than the total duration of smoking. The similar past
smoking rates in the SS and non-SS sicca groups suggest that there is not an intrinsic difference between the groups regarding confounding factors that are associated with tobacco smoking. We performed a detailed analysis of known covariates of smoking, including SES,
education, income, BMI, and alcohol and caffeine intake, and none of them were independent
predictors of Sjögren’s classification. The overall current smoking rate of the cohort, irrespective of classification as SS or non-SS sicca, was significantly lower than expected based on the
community smoking rates, even when adjusting for age, race, and gender. Given that the past
smoking rates of the cohort as a whole are similar to the population rates, the low current
smoking can only be explained by an increase in smoking cessation. A plausible explanation is
that the mucosal drying and irritation caused by smoking are an effective deterrent in patients
suffering from dryness.[42] This is further supported by the observed lower current smoking
rate among non-SS sicca patients compared to the SLE and community comparison groups,
despite similar past smoking rates.
The effects of tobacco on SS manifestations were confined to measures of objective autoimmunity. The proportion of study participants that reported subjective dry eyes and dry mouth
was comparable between SS and non-SS sicca subjects, and also across all smoking behaviors.
Furthermore, there were no significant differences in objective measures of lacrimal and salivary production between smokers and non-smokers. Previous studies have suggested that the
main ocular surface effects of tobacco smoking are associated with abnormal tear breakup
time rather than aqueous tear production;[40] this is likely the reason for the lack of association of smoking status with the Schirmer’s and ocular surface staining tests. Smoking has been
associated with contradictory effects on salivary flow rate; in healthy patients, the short-term
effect is increased saliva production that eventually leads to decreased salivary flow rate.[43]
Neither our study nor earlier studies in SS patients have found significant effects of tobacco on
whole unstimulated salivary flow.[31]
The most significant negative association of smoking was with a focus score 1 and with
focal lymphocytic sialadenitis on the MSG biopsy; the mean focus score of smokers was also
lower but did not reach statistical significance. These differences were observed when comparing current smoking to past, ever and/or never smokers. A previous study of SS patients had
similar findings to our results, confirming lower MSG biopsy focus scores amongst current
smokers albeit a detailed analysis of histopathologic features of the biopsies was not discussed.
[31] Our results show not only that smokers are less likely to present with focal lymphocytic
sialadenitis and focus scores 1, but also that they have significantly more non-specific
chronic inflammation. These results suggest that the exposure to tobacco smoke protects
against the formation of organized lymphocytic infiltrates in the salivary gland. The
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characteristic focal lymphocytic infiltrates in the exocrine glands of SS patients consist predominantly of activated CD4+ T lymphocytes (>75%) with B cells appearing in later stages of
the disease.[44] The salivary gland pathology is mainly Th-1 mediated, particularly in cases
with high focus scores, while activation of IL-17 secreting T-cells in the SS infiltrates promote
the formation of germinal centers.[45, 46] Studies have shown that smoking causes a dosedependent decrease in the number of CD4+ T cells, and that T cells from smokers proliferate
poorly in response to T-cell mitogens.[47] Nicotine blocks pro-inflammatory cytokines with
notable effects on IL-6, TH1, and IL-17-mediated responses.[48] Furthermore, chronic exposure to benzo[a]pyrene, an important component of cigarette smoke, results in decreases in
the mass and cellularity of lymphoid tissues.[49]
When the exposure to cigarette smoke is sustained, a chronic inflammatory process is triggered that promotes enhanced microbial colonization and infection, persistence of apoptotic
material and abnormal processing of cellular debris, with the potential to induce the architectural remodeling characteristic of chronic inflammation[50]. Several studies have shown that
nicotine alters the morphology of salivary gland tissue. A study of parotid glands of rats
exposed to nicotine in drinking water, demonstrated atrophy and swelling of acinary cells with
an increase in the total intraacinar secretory granulae[51]; furthermore, smoke-exposed glands
exhibit enlarged intercalated and striated ductal portions[52]. Additional cigarette-smoke
effects are the dysregulation of innate immune responses in the oral cavity by modifying local
TLR expression, distribution, and activation[53], thus promoting an environment permissive
for chronic inflammation[54, 55]. So while tobacco has local inflammatory effects, its immunomodulatory mechanisms may underlie the reduced organized lymphocytic infiltration of
the salivary gland observed in smoker SS patients and the preponderance on chronic non-specific inflammation.
In addition to the local exocrine gland pathology, patients with SS have alterations in the
neuroendocrine system including the hypothalamus-pituitary-adrenal axis (HPA), the hypothalamic-pituitary-gonadal axis and the autonomic nervous system.[56] The HPA and autonomic nervous systems modulate local and systemic immune responses through nicotinic
receptors in the brain, while non-neuronal nicotinic acetylcholine and cholinergic receptors in
the periphery have been shown to modulate the Th17 response in CD4+ T lymphocytes[57].
Nicotine has been used experimentally in the management of ulcerative colitis, endometriosis,
and sarcoidosis, but well-founded concerns about nicotine’s detrimental long-term and addictive effects have limited its therapeutic applications[10]. The exploration of alternative and
selective nicotinic receptor agonists may lead to novel therapeutic options for the treatment of
inflammatory and autoimmune disorders, including Sjögren’s Syndrome.
The presence of autoantibodies against Ro/SSA and La/SSB are characteristic of SS; the
overall rate of anti-Ro/SSA(+) and anti-La/SSB(+) in our cohort is 31% and 20%, respectively
(61% and 40% in SS patients). This is in contrast with the significantly lower 12% anti-Ro/SSA
(+) and 10% anti-La/SSB amongst current smokers. We did not observe any significant differences in the proportion of positive ANA and rheumatoid factor (RF). As is the case with salivary flow rates, the relationship between smoking and autoantibodies has historically been
contradictory (Table 6). Long-term smoking significantly reduces serum levels of immunoglobulins in humans but may increase the levels of some autoantibodies, in particular ANA.
[10] Decreased prevalence of anti-Ro/SSA antibodies amongst patients with SS had been
reported by Bartoloni et al[26] and of both antiRo/SSA and anti-La/SSB by Manthorpe et al.;
[31] however, the study by Karabulut only found a positive association of current smoking
with elevated ANA[29]. The results are also inconsistent in other autoimmune disorders.
Some studies of SLE patients demonstrated an increased expression of anti-dsDNA antibodies
amongst smokers [58] while other investigators did not find a clear association between
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Table 6. Studies on the association between smoking and Sjögren’s Syndrome
Author
Stone et al

Study Population

Study Objective

587 pSSa
701 non-SS sicca USA single center
1242 SLE

Prevalence of smoking in SS and association
of smoking habits with clinical features and
risk of SS

981 unaffected first-degree relatives
and 946 healthy controls from USA
LFRR registry

Effects of tobacco smoking
Lower prevalence of pSS
Lower frequency of FS1

Ref
Current
study

Lower prevalence of focal
lymphocytic sialadenitis
Higher prevalence of non-specific
chronic inflammation of minor salivary
glands
Lower frequency of anti-Ro/SSA +
Lower frequency of anti-La/SSB +
Inverse correlation between smoking
duration and SS risk

Bartoloni
et al

Nilsson et al

788 pSSa from 5 Italian centers
4774 control females from Registry of
Italian General Population
51 pSSa Malmö, Sweden
186 control females from Uppsala
general health survey

Manthorpe
et al

355 pSSa Malmö, Sweden

Compare prevalence of traditional
cardiovascular disease risk factors and over
disease

Lower frequency of anti-Ro/SSA +

Prevalence of COPD with pSS and its
association with cigarette smoking

Increased risk of COPD in pSS even
amongst non-smokers

3700 age and sex matched controls
from general population
Karabulut
et al

Lower prevalence of pSS

Correlation of smoking habits with focus score Lower frequency of FS1
in lower lip biopsies, serum antibodies and IgG Lower frequency of anti-Ro/SSA +

35 stomatitis sicca

207 pSSa Turkey
602 gender matched healthy controls

(26)

Lower frequency of anti-La/SSB +
(27)

(31)

Lower frequency of anti-La/SSB +
Frequency of smoking in pSS and correlation
with autoantibodies and extraglandular
manifestations

a

Lower current smoking in pSS

(29)

Higher past or never smoking in pSS
Higher frequency of ANA +

31

Subjects are classified as primary Sjögren’s Syndrome based on the AECG criteria

doi:10.1371/journal.pone.0170249.t006

smoking status and individual autoantibodies.[37] In the case of RA patients, smoking has
been associated with increased ANA positivity in men and RF in women.[59, 60] These seemingly opposite results suggest that the role of smoking on pathogenic autoantibodies differs
from one autoimmune disease to another and may be a good example of gene-environment
interaction.
The effects of tobacco have been shown to be proportional to lifetime exposure, so that former smokers have intermediate levels of disease features associated with tobacco in comparison to current and never smokers.[3] Measures of exposure include smoking duration, time
since cessation, and intensity of smoking. Unfortunately, the smoking data collected in our study
does not allow us to measure the intensity of smoking, measured as pack-per-year, so the doseresponse analysis was limited to duration of exposure rather than the dosage of tar and nicotine
as potential factors influencing our results. Similarly, we did not take into account other tobacco
delivery systems that may influence the doses of each chemical; it has been reported that high
levels of tar and nicotine induce immunosuppression faster and possibly for longer time than
cigarette smoke with lower levels.[10] Animal models treated with nicotine were immunosuppressed for several weeks after cessation; similarly, patients with ulcerative colitis remained
relapse free for several months after the end of nicotine treatment[10]. The effect of cessation
was not replicated in our study, possibly because the vast majority of ever smokers discontinued
smoking long before being diagnosed with either SS or non-SS. However, duration of smoking
was significantly and inversely correlated with SS classification; to rule out that this was a
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spurious effect, we controlled for potential confounding factors by detailed multivariate analyses
[39] and confirmed that smoking duration was an independent effect.
While we are aware of the significant limitations of a cross-sectional observational study
like ours, we are encouraged by the solidity of our preliminary findings. Any probabilistic
causal association between tobacco and SS would have to survive scrutiny for temporal relationship, biological plausibility, consistency with other independent studies, elimination of
confounding factors, dose-response relationship, strength of association and cessation of
effects[61, 62]. Our data support most of these factors, with the underlying biological mechanisms being the least explored but most attractive area of future exploration. Designing a prospective, longitudinal study of those at high risk for developing SS may shed light on the
nature of the negative association with tobacco smoking and pinpointing the chemicals within
the tobacco smoke responsible for the protective effects could open new avenues for understanding physiopathogenic pathways and potential therapeutic targets.
However, it is of the upmost importance to highlight that given the overwhelming negative
effect of tobacco use on health, smoking cessation should be recommended to patients with
Sjögren’s syndrome who are already at higher risk for malignancy, pulmonary and cardiovascular disease.
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